Janux Therapeutics, Inc. Common Stock (JANX) is a publicly traded Healthcare sector company. As of September 8, 2026, JANX trades at $19.83 with a market cap of $1.24B and a P/E ratio of -12.12. JANX moved -0.89% today. Year to date, JANX is +45.22%; over the trailing twelve months it is -19.23%. Its 52-week range spans $12.12 to $47.58. Analyst consensus is strong buy with an average price target of $34.22. Rallies surfaces JANX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for JANX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $19.83 |
| Market Cap | $1.24B |
| P/E Ratio | -12.12 |
| EPS | $-1.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $47.58 |
| 52-Week Low | $12.12 |
| Volume | 797.26K |
| Avg Volume | 0 |
| Revenue (TTM) | $24.00M |
| Net Income | $-102.59M |
| Gross Margin | 0.00% |
11 analysts cover JANX: 0 strong buy, 10 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.22.